01重点学术场次Priority Sessions17 场
本专题的重点场次包含 Hot Line、LBCS、New ESC Guidelines、Ask the Trialists、Guidelines in Practice、Great Debates 等。
指南与标准7 场
New Guidelines
2026 ESC 指南与文件概览
2026 ESC Guidelines and Document overview
New Guidelines
2026 ESC 心力衰竭管理指南
2026 ESC Guidelines for the Management of Heart Failure
New Guidelines
2026 ESC 心血管疾病与慢性肾脏病管理指南
2026 ESC Guidelines for the Management of Cardiovascular Disease and Chronic Kidney Disease
SGLT2 抑制剂3 场Hot Line 1
Hot Line
HOT LINE 5（全球首发专场）
HOT LINE 5
EMAIL-HF：通过数字化策略在心衰患者中落地 SGLT2 抑制剂
EMAIL-HF: Implementation of SGLT2 inhibitors in patients with heart failure through a digital strategy
远程运动 SWEDEHEART：心脏远程康复的整群随机交叉试验
Remote Exercise SWEDEHEART: a cluster randomized cross-over trial on cardiac telerehabilitation
ADHERE-ASCVD：适应性数字化外呼改善他汀依从性
ADHERE-ASCVD: Adaptive Digital Outreach for Statin Adherence
VIRTUES ICD：植入式心脏复律除颤器虚拟电子健康系统与 VIRTUES PM：起搏器数字健康平台
VIRTUES ICD: Virtual E-health system for Implantable Cardioverter Defibrillators and VIRTUES PM: Digital health platform for pacemakers
LBCS
心力衰竭：肾脏是关键
Heart failure: the kidney is key
肾功能下降、心衰住院与恩格列净在心衰中的效应：EMPEROR 汇总分析
Kidney Function Decline, Heart Failure Hospitalization and the Effect of Empagliflozin in Heart Failure: An EMPEROR-Pooled Analysis
心衰试验中肾小球滤过率斜率作为肾病进展替代终点：个体患者数据荟萃分析
Glomerular filtration rate slope as a surrogate endpoint for kidney disease progression in heart failure trials: An individual participant data meta-analysis
预测心力衰竭疗法及其联合方案对血压、肾功能和血钾的短期影响
Predicting Short-term Effects on Blood Pressure, Kidney Function, and Serum Potassium with Heart failure Therapies and their Combinations
多器官脂肪分布的精准表型分型定义不同的心肾代谢与心力衰竭风险谱
Precision Phenotyping of Multi-Organ Fat Distribution Defines Distinct Cardiorenal-Metabolic and Heart Failure Risk Profiles
LBCS
晚期临床科学：优化心力衰竭预后
Late-Breaking Clinical Science: optimising outcomes in heart failure
心力衰竭静脉补铁随机试验：个体患者数据荟萃分析
Randomised intravenous iron trials for heart failure: an individual-patient-data meta-analysis
院内启动达格列净对急性心衰去充血相关终点的影响：DAPA ACT HF-TIMI 68 试验预设分析
Effect of In-Hospital Initiation of Dapagliflozin on Decongestion-Related Endpoints in Acute Heart Failure: A Prespecified Analysis of the DAPA ACT HF-TIMI 68 Trial
全磁悬浮左心室辅助装置下的肥胖、衰弱性肥胖与临床结局：MOMENTUM 3 试验
Obesity, Frail Obesity, and Clinical Outcomes with a Fully Magnetically Levitated Left Ventricular Assist Device: the MOMENTUM 3 Trial
心衰治疗、发病与死亡率的演变趋势：意大利心衰网络（IN-HF）注册研究 30 年数据
Evolving Trends in Treatments, Morbidity, and Mortality in Heart Failure: 30 Years of Data from the Italian Network of Heart Failure (IN-HF) Registry
淀粉样变（ATTR-CM）1 场
LBCS
晚期临床科学：心力衰竭诊断与预后登记研究
Late-Breaking Clinical Science on heart failure: diagnosis and prognosis registries
按射血分数表型与国家收入水平分层的 19,397 名受试者死亡率与住院率：全球充血性心衰注册研究
Mortality and hospitalization rates in 19,397 participants according to ejection fraction phenotype and country income level: The Global Congestive Heart Failure Registry.
ECG Flow ATTR：AI 赋能心电图早期诊断转甲状腺素蛋白心脏淀粉样变
ECG Flow ATTR: Artificial Intelligence Enabled Early Diagnosis of Transthyretin Cardiac Amyloidosis Using Electrocardiography
疑似心力衰竭患者 NT-proBNP 与临床特征的个体化评估
Personalised Evaluation of NT-proBNP and Clinical Characteristics in Suspected Heart Failure
主动筛查识别 ST 段抬高型心肌梗死后的未被识别的心力衰竭
Proactive screening identifies unrecognized heart failure after ST-elevation myocardial infarction
洋地黄类药物1 场
LBCS
心力衰竭中的洋地黄苷：回归未来
Digitalis glycosides in heart failure: back to the future!
早用晚用皆获益？HFrEF 中地高辛作用再审视：DIG 试验的启示
Early or late, benefits of digoxin reconsidered in HFrEF: Insights from the Digitalis Investigation Group Trial (DIG)
HFrEF 患者地高辛毒素随时间推移的疗效：DIGIT-HF 进一步分析
Efficacy of digitoxin over time in patients with HFrEF: further analysis of DIGIT-HF
小剂量地高辛治疗女性和男性心衰：DECISION 数据
Low-dose Digoxin in Women and Men with Heart Failure: Data from DECISION
DIGIT-HF 分析：地高辛毒素治疗射血分数降低型心衰的长期成本效益
Long-term cost-effectiveness of digitoxin in heart failure with reduced ejection fraction analyzed in DIGIT-HF
血管扩张剂（肼屈嗪/硝酸酯）1 场Hot Line 1
Hot Line
HOT LINE 6（全球首发专场）
HOT LINE 6
H-HeFT：肼屈嗪-硝酸异山梨酯治疗 HFrEF
H-HeFT: Hydralazin-Isosorbide Dinitrate in HFrEF
H-ISDN 荟萃分析：肼屈嗪-硝酸异山梨酯治疗 HFrEF
H-ISDN Meta-Analysis: Hydralazine-Isosorbide Dinitrate in HFrEF
Met-HeFT：二甲双胍与慢性心力衰竭
Met-HeFT: Metformin and chronic heart failure
Met-HeFT 荟萃分析：二甲双胍治疗心衰与缺血性心脏病：系统评价与荟萃分析
Met-HeFT meta-analysis: Metformin in heart failure and ischemic heart disease: a systematic review and meta-analyses
LUMINARA：每日一次口服松弛素激动剂治疗心衰的前瞻性随机对照试验
LUMINARA: a prospective RCT of a once daily oral relaxin agonist for treating heart failure
PADN-PH-LHD：肺血管去神经治疗心衰所致肺动脉高压
PADN-PH-LHD: PADN for patients with PH from heart failure
TIME-HF：心力衰竭的团队协作诊疗模式
TIME-HF: Team-based collaborative care model in Heart Failure
GLP-1 与代谢药物之争1 场
Great Debates
焦点辩论：所有心衰患者都应使用 GLP-1 受体激动剂吗
Great Debate: should all patients with heart failure be treated with GLP-1 receptor agonists?
所有心力衰竭患者都应使用 GLP-1 受体激动剂
All patients with heart failure should be treated with GLP-1 RAs
正方Mark C PetrieUniversity of Glasgow反方Laura MeemsUniversity Medical Centre Groningen评论员Adriaan VoorsUniversity Medical Centre Groningen
HFpEF1 场
Great Debates
焦点辩论：HFpEF 患者应否接受房颤消融
Great Debates: should atrial fibrillation ablation be performed in patients with HFpEF?
HFpEF 患者应接受房颤消融
Atrial fibrillation ablation should be performed in patients with HFpEF
正方Luigi Di BiaseAlbert Einstein Medical Center反方Carolyn S P LamDuke-NUS Graduate Medical School Singapore评论员Pier LambiaseBarts Heart Centre
新诊断 HFrEF 中可穿戴除颤器是预防猝死的宝贵方案
In newly discovered HFrEF the wearable defibrillator is a valuable solution for preventing sudden death
正方David DunckerHannover Heart Rhythm Center反方Ileana PinaThomas Jefferson University评论员Milton PackerBaylor University Medical Center
心脏再同步与起搏器械1 场Hot Line 1
Hot Line
HOT LINE 10（全球首发专场）
HOT LINE 10
ASPIRED：不明原因急性晕厥患者即时增强动态心电图监测对比标准监测的多中心开放标签随机对照试验
ASPIRED: Multi-centre open label randomised controlled trial of immediate enhanced ambulatory ECG monitoring versus standard monitoring in acute unexplained syncope patients
DANISH-CRT：心衰双心室起搏的靶向左室电极植入
DANISH-CRT: Targeted LV lead placement for biventricular pacing for heart failure
SyncAV PMT：心脏再同步化治疗中动态房室间期优化的临床获益
SyncAV PMT: Clinical Benefit of Dynamic AV Optimization in CRT
Syncope-Stopper：高危不明原因晕厥的早期起搏与标准治疗比较
Syncope-Stopper: Upfront Pacing vs Standard Care in High-Risk Unexplained Syncope
希氏束起搏替代方案 II
HIS Alternative II
心肌肌球蛋白抑制剂（HCM）1 场
LBCS
心脏重塑：心肌病与心力衰竭的新型治疗
Transforming the heart: novel therapies for myocardial disease and heart failure
冠脉内 AAV1/SERCA2a 基因治疗 HFpEF 患者的结局：MUSIC-HFpEF 1/2a 期试验 12 个月结果
Outcomes of Intracoronary AAV1/SERCA2a Gene Therapy in Patients With Heart Failure With Preserved Ejection Fraction: 12-Month Results From the MUSIC-HFpEF Phase 1/2a Trial
CIRRUS-HCM：新型心肌肌节调节剂 EDG-7500 治疗非梗阻性与梗阻性肥厚型心肌病 12 周安全性与疗效评估
CIRRUS-HCM: 12-Week Evaluation of the Safety and Efficacy of the Novel Cardiac Sarcomere Modulator EDG-7500 in Nonobstructive and Obstructive Hypertrophic Cardiomyopathy
自体调节生物瓣全人工心脏治疗晚期双心室衰竭：EFICAS 研究 180 天结局
The autoregulated bioprosthetic total artificial heart in advanced biventricular failure: 180-day outcomes from the EFICAS study
静脉右雷佐生治疗 STEMI 出血性心肌梗死：双盲、安慰剂对照、序贯队列 IIa 期试验（SHIELD-MI）
Intravenous Dexrazoxane for Hemorrhagic Myocardial Infarction in STEMI: A Double-Blind, Placebo-Controlled, Sequential-Cohort Phase IIa Trial (SHIELD-MI)
02中国专家参与场次China Faculty1 场
| 中国专家参与的报告 |
|---|
| 血管扩张剂（肼屈嗪/硝酸酯） · 1 项中国专家报告 |
PADN-PH-LHD：肺血管去神经治疗心衰所致肺动脉高压 PADN-PH-LHD: PADN for patients with PH from heart failure |
03本领域中国研究China Abstracts57 篇
| 研究标题 | 第一作者 | 所在机构 |
|---|---|---|
| 流行病学、预后与结局 · 12 篇 | ||
症状限制性心肺运动试验对心力衰竭患者复合临床结局与超声重构的预后价值：前瞻性队列研究 Prognostic value of symptom-limited cardiopulmonary exercise testing outcomes on composite clinical outcomes and echocardiographic remodeling in patients with heart failure: a prospective cohort study | Chengyi Wang | 中国医学科学院北京协和医学院阜外医院 |
急性失代偿性心力衰竭患者院内血钾变化与临床结局 In-hospital potassium changes and clinical outcomes in patients with acute decompensated heart failure | Chin-Chou HUANG | 阳明交通大学 |
累积静息心率负荷与心力衰竭患者的心血管风险：五项随机临床试验的二次分析 Cumulative resting heart rate load and cardiovascular risk in patients with heart failure: a secondary analysis of five randomized clinical trials | Jun Hao | 南昌大学第一附属医院 |
心力衰竭患者慢性高钾血症风险预测模型：NORMALIZE研究结果 Risk prediction model for chronic hyperkalemia in patients with heart failure: results from NORMALIZE study | Zuolin Li | 东南大学附属中大医院 |
肥胖削弱N末端B型利钠肽前体在心力衰竭中的预后价值 Obesity blunts the prognostic value of N-terminal pro-brain natriuretic peptide in heart failure | Yilan Ge | 北京医院 |
急诊科基于ESC临床表型的急性心力衰竭早期风险分层 Early risk stratification of acute heart failure using ESC-defined clinical phenotypes in the emergency department | Hanyang Liang | 国家心血管病中心、阜外医院心血管疾病国家重点实验室 |
基于生存机器学习的心衰再入院风险预测：整合新型可穿戴心音多模态参数与临床指标的前瞻性队列研究 Prediction of heart failure readmission risk based on survival machine learning: a prospective cohort study integrating novel wearable cardiac acoustic multimodal parameters and clinical indicators | Chao Yu | 南昌大学第二附属医院 |
系统炎症、他汀治疗与心力衰竭临床结局：全港人群队列研究 Systemic inflammation, statin therapy, and clinical outcomes in heart failure: a territory-wide population-based cohort study | Anping Cai | 广东省人民医院 |
左束支传导阻滞与心肌病对新发心力衰竭的联合关联：英国生物样本库前瞻性队列研究 Joint association of left bundle branch block and cardiomyopathy with incident heart failure: a prospective UK Biobank cohort study | Sijing Cheng | 中国医学科学院北京协和医学院阜外医院 |
1186例心脏移植终末期心力衰竭患者的全基因组景观 Whole-genome landscapes of 1186 end stage heart failure patients undergoing heart transplantation | Shanshan Xu | 国家心血管病中心、阜外医院心血管疾病国家重点实验室 |
CT衍生脂肪组织密度反映系统炎症负荷并独立预测老年HFpEF患者死亡率 CT-derived adipose tissue density reflects systemic inflammatory burden and independently predicts mortality in elderly patients with HFpEF | Kailei Shi | 华东医院 |
住院心力衰竭患者出院后一个月高钾血症风险预测模型：中国全国注册队列研究 Risk prediction model for one-month post-discharge hyperkalemia in hospitalized heart failure patients: a nationwide registry cohort study in China | Yingying Li | 北京医院 |
| 射血分数保留的心衰 · 12 篇 | ||
ω-6/ω-3多不饱和脂肪酸代谢失衡通过ANGPTL4/LPL轴介导的脂毒性促进HFpEF进展 Imbalanced ω-6/ω-3 polyunsaturated fatty acid metabolism promotes HFpEF progression via the ANGPTL4/LPL axis-mediated lipotoxicity | Zhanyi Zhang | 西安交通大学第一附属医院 |
PCWP表征HFpEF人群中左束支区域起搏的应答者 PCWP characterizes responders of left bundle branch area pacing in HFpEF population | Yang Su | 上海市第十人民医院 |
SGLT2抑制剂对极高龄射血分数保留型心力衰竭患者的生存获益 Survival benefits of SGLT2 inhibitors in very elderly patients with heart failure with preserved ejection fraction | Yilan Ge | 北京医院 |
按ATTR-CM风险分层的HFpEF临床结局与治疗反应：真实世界队列研究 Clinical outcomes and treatment response according to ATTR-CM risk in HFpEF: a real-world cohort study | Cheng-En Tsai | 台湾大学附属医院 |
BMI与HFpEF一年结局的非线性关联及跨BMI水平一致的治疗效果：中国全国注册研究的启示 Nonlinear association of body mass index with 1-year outcomes and consistent treatment effects across BMI in HFpEF: insights from a nationwide chinese registry | Jingmin Zhou | 中山医院 |
整合血浆与尿液代谢组学揭示高血压驱动心力衰竭的代谢介质 Integrated plasma and urinary metabolomics reveal metabolic mediators of hypertension-driven heart failure | Liming Chen | 中山医院 |
HFsnEF与HFnEF的蛋白组与代谢组景观识别HFpEF分子亚型与预后标志物 Proteomic and metabolomic landscapes of HFsnEF and HFnEF Identify molecular subtypes and prognostic markers in HFpEF | Jingyi Ren | 中日友好医院 |
揭示超常表型：内在心肌病驱动射血分数超常心力衰竭患者的不良结局 Unmasking the supernormal: intrinsic cardiomyopathy drives poor outcomes in heart failure with supranormal ejection fraction | Yanjia Chen | 上海交通大学医学院附属瑞金医院 |
射血分数保留型心力衰竭患者LDL-C水平与结局的关联：真实世界研究 Association between LDL-C levels and outcomes in patients with heart failure with preserved ejection fraction: a real-world study | Shichen Jiang | 天津医科大学总医院 |
吲哚硫酸盐(IS)-CTSK轴介导CKD相关HFpEF中心脏成纤维细胞激活 Indoxyl sulfate (IS)-CTSK axis mediates cardiac fibroblast activation in CKD-Related HFpEF | Yuanming Zou | 上海交通大学医学院附属仁济医院 |
GPRER激动减轻卵巢切除HFpEF小鼠线粒体功能障碍与心功能障碍 GPER stimulation attenuates mitochondrial dysfunction and cardiac dysfunction pathway in ovariectomized mice with HFpEF | Jing Yu | 兰州大学第二医院 |
心脏代谢HFpEF的预后与治疗反应：深度学习表型绘图与实用临床分类器 Prognosis and treatment response in cardiometabolic HFpEF: deep learning-based phenomapping with a pragmatic clinical classifier | Xinwei Hua | 北京大学第三医院 |
| 心室重构 · 8 篇 | ||
术后早期左室变化有助于识别原发性瓣膜反流患者的残留瓣膜性心肌病 Early post-surgery left ventricular changes helps to identify patients with residual valvular cardiomyopathy in primary valvular regurgitation | Yu Kang | 四川大学华西医院 |
新生儿筛查开启晚发型法布里病的治疗窗口：早期治疗后长期分化的重构轨迹 A newborn screening–enabled therapeutic window in late-onset fabry disease: long-term divergent remodeling trajectories with early-stage treatment | Kuo-Tzu Sung | 马偕纪念医院 |
靶向成纤维细胞CTHRC1通过抑制心肌细胞NLRP3炎症小体激活改善心脏纤维化与功能障碍 Targeting fibroblast CTHRC1 ameliorates cardiac fibrosis and dysfunction by suppressing cardiomyocyte NLRP3 inflammasome activation | Xiaoqing Wang | 四川省人民医院 |
AI辅助纵向心脏表型分析促进法布里心肌病领域特异性重构轨迹的识别 AI-assisted longitudinal cardiac phenotyping facilitated identification of domain-specific remodeling trajectories in fabry cardiomyopathy | Kuo-Tzu Sung | 马偕纪念医院 |
NRAP标记病理心脏重构过程中的适应性前肌纤维样结构 NRAP marks adaptive premyofibril-like structures during pathological cardiac remodeling | Tianshuo Yang | 中国医学科学院北京协和医学院阜外医院 |
远程监测指导快速指南导向药物上调对新发急性射血分数减低型心力衰竭左室逆向重构的影响 Impact of telemonitoring-guided rapid guideline-directed medical therapy escalation on left ventricular reverse remodeling in new-onset acute heart failure with reduced ejection fraction. | Xiayan Xu | 香港大学 |
Z盘机械感知完整性决定心脏逆向重构：多尺度成像与基因编辑大鼠模型的启示 Z-disc mechanosensory integrity dictates cardiac reverse remodeling: insights from multiscale imaging and gene-edited rat models | Hongtian Wang | 国家心血管病中心、阜外医院心血管疾病国家重点实验室 |
非经典VEGFA N端肽作为核调控因子驱动年龄依赖性心脏重构 Non-canonical VEGFA N-terminal peptide functions as a nuclear regulator driving age-dependent cardiac remodelling | Zhongxiang Chen | 上海交通大学 |
| 射血分数降低的心衰 · 5 篇 | ||
整合多组学分析揭示去肾神经术缓解糖尿病心肌病的分子机制 Integrated multi-omics analysis reveals the molecular mechanisms of renal denervation in alleviating diabetic cardiomyopathy | Feng Zhang | 天津市第一中心医院 |
心力衰竭患者心肌机械强度主要取决于胶原纤维含量 The mechanical strength of the myocardium in patients with heart failure is primarily determined by the collagen fiber content | Tao Shi | 西安交通大学第一附属医院 |
心肌瘢痕负荷而非机械不同步或应变决定HFrEF的恢复潜力：CMR研究 Myocardial scar burden, not mechanical dyssynchrony or strain, dictates recovery potential in HFrEF: a CMR study | Chen Die Yang | 上海交通大学医学院附属瑞金医院 |
维立西呱治疗高危HFrEF期间左心逆向重构 Cardiac reverse remodelling of left heart during vericiguat therapy for high-risk HFrEF | Alex Pui-Wai Lee | 香港中文大学 |
传统中药芪苈强心对沙库巴曲缬沙坦治疗HFrEF患者的效果：QUEST试验 Effect of traditional Chinese medicine Qiliqiangxin in patients With HFrEF treated with sacubitril/valsartan: the QUEST trial | Iok Fai Cheang | 南京医科大学第一附属医院 |
| 合并症 · 4 篇 | ||
血红蛋白浓度能否定义女性与男性贫血？ Can haemoglobin concentration define anaemia in women and men? | Zihao Huang | 香港大学 |
心力衰竭试验中eGFR与CKD分类的跨国差异：QUEST、PARADIGM-HF与DAPA-HF五种方程比较分析 Cross-national disparities in eGFR and CKD classification in HF trials: a comparative analysis of five equations in QUEST, PARADIGM-HF, and DAPA-HF | Li Shen | 杭州师范大学 |
心力衰竭患者左房重构与内囊微结构损伤：基于左房最大容积指数分层的比较 Left atrial remodeling and microstructural damage in the internal capsule in heart failure: a comparison based on left atrial maximum volume index stratification | Cunxue Pan | 中山大学附属第五医院 |
04企业卫星会Industry Symposia23 个系列
赞助商分布13 场 · Boehringer Ingelheim 6 场 · Philips Healthcare 6 场 · Bayer AG 5 场 · AstraZeneca 2 场 · Siemens Healthineers 2 场 · Abbott 1 场 · Carmat 1 场 · Servier 1 场 · Novo Nordisk 1 场 · Charité
指南与标准4 个系列
Boehringer Ingelheim
改善结局：推进心衰门诊的指南指导治疗
Building better outcomes: advancing guideline-directed outpatient care in heart failure
为心力衰竭基础门诊诊疗奠定基础
Setting the scene for foundation-building outpatient care in heart failure
奠定基础：指南支持的 SGLT2 抑制剂用于整个射血分数谱
Laying the groundwork: guideline-supported SGLT2 inhibitor use across the ejection fraction spectrum
打破壁垒：克服临床惰性与实施挑战
Breaking down the walls: overcoming clinical inertia and implementation challenges
夯实基础：推进慢性肾脏病、2 型糖尿病与已确诊心血管疾病患者的心血管风险降低
Strengthening the foundation: advancing cardiovascular risk reduction in chronic kidney disease, type 2 diabetes, and established cardiovascular disease
扩展框架：推进心脏病学家对心血管风险降低的主导
Expanding the framework: advancing cardiologist ownership of cardiovascular risk reduction
构建更好结局：推进心衰指南指导的门诊管理——讨论与问答
Building better outcomes: advancing guideline-directed outpatient care in heart failure - Discussion and Q&A
… 另 1 项讲题
Boehringer Ingelheim
尽早启动、住院启动：心衰指南落地实践
Start early, start in hospital: translating heart failure guidelines into practice
欢迎与介绍：错失机会的代价
Welcome and introduction: the cost of a missed opportunity
尽早启动的理由：为何现在行动？
The case for early initiation: why act now?
证据表明：院内早期应用 SGLT2 抑制剂的实践
What the evidence shows: early in-hospital SGLT2 inhibitor use in practice
从证据到行动：院内实用
From evidence to action: practical use in hospital
出院及以后：为患者长期获益铺路
Discharge and beyond: setting patients up for long-term success
尽早启动、院内启动：将心力衰竭指南转化为实践——讨论与问答
Start early, start in hospital: translating heart failure guidelines into practice - Discussion and Q&A
… 另 1 项讲题
Charité
非甾体类盐皮质激素受体拮抗剂治疗心衰：从里程碑证据到指南实践
Non-steroidal mineralocorticoid receptor antagonists (nsMRAs) in heart failure: translating landmark evidence into guideline-directed practice
欢迎与介绍
Welcome and introduction
非甾体类盐皮质激素受体拮抗剂在心力衰竭指南中的定位：我们处于何处？
Positioning nsMRAs in heart failure guidelines: where do we stand?
nsMRA 在心力衰竭患者中的证据基础
The evidence base for nsMRAs in patients with heart failure
如何将指南中非甾体类盐皮质激素受体拮抗剂的推荐转化为实践？
How to translate the guideline recommendations for nsMRAs into practice?
专家讨论
Panel discussion
总结
Conclusion
AstraZeneca
Troubleshooting heart failure: optimising guideline-directed medical therapy in real-world（系列共 2 场）
心力衰竭排查：真实世界中优化指南指导的药物治疗
Troubleshooting heart failure: optimising guideline-directed medical therapy in real-world practice
AI 与数字技术5 个系列
Philips Healthcare
AI 驱动的心衰超声：表型分析、高级量化、监测与决策支持
Artificial intelligence-driven echo in heart failure: phenotyping, advanced quantification, monitoring, and clinical decision support
AI 驱动的心衰超声：表型分析、高级量化、监测与临床决策支持
Artificial intelligence-driven echo in heart failure: phenotyping, advanced quantification, monitoring, and clinical decision support
Philips Healthcare
瓣膜病合并心衰：AI 引导评估与疑难病例讨论（系列共 2 场）
Heart failure in valvular disease: artificial intelligence‑guided assessment and complex case discussions
瓣膜病中的心衰：AI 引导评估与复杂病例讨论
Heart failure in valvular disease: artificial intelligence‑guided assessment and complex case discussions
Philips Healthcare
大师课：AI 引导的心衰评估——从扫查技巧到复杂病例管理
Master Class - artificial intelligence‑guided heart failure assessment: from scanning tips to complex case management
大师课——AI 引导的心衰评估：从扫描技巧到复杂病例管理
Master Class - artificial intelligence‑guided heart failure assessment: from scanning tips to complex case management
Philips Healthcare
Master class — Artificial intelligence‑guided heart failure assessment: from scanning tips
大师课——AI 引导的心衰评估：从扫描技巧到复杂病例管理
Master class — Artificial intelligence‑guided heart failure assessment: from scanning tips to complex case management
Philips Healthcare
心衰与瓣膜病的扫查方案：AI 优化的图像采集、量化与端到端报告
Scanning protocols for heart failure and valvular heart disease: artificial intelligence‑optimised acquisition, quantification and end‑to‑end reporting
心力衰竭与瓣膜性心脏病的扫描方案：AI 优化的采集、量化与端到端报告
Scanning protocols for heart failure and valvular heart disease: artificial intelligence‑optimised acquisition, quantification and end‑to‑end reporting
HFpEF3 个系列
Bayer AG
夯实基础治疗：非奈利酮作为 HFmrEF/HFpEF 的核心治疗支柱
Implementing foundational care: finerenone as a core treatment pillar in HFmrEF/HFpEF
演进中的心衰诊疗：非奈利酮在当今治疗格局中的作用
Evolving heart failure care: finerenone’s role in today’s treatment landscape
数据驱动的决策：区分非奈利酮与甾体类盐皮质激素受体拮抗剂
Making data-driven decisions: distinguishing finerenone from steroidal MRAs
在临床实践中落地非奈利酮：优化指南指导治疗
Implementing finerenone in clinical practice: optimising guideline-directed therapy
实施基础照护：非奈利酮作为 HFmrEF/HFpEF 的核心治疗支柱——听众问答
Implementing foundational care: finerenone as a core treatment pillar in HFmrEF/HFpEF - Audience Q&A
Bayer AG
引领照护：HFpEF 合并多病患者的优化指南指导治疗（系列共 2 场）
Leading care – implementing optimal guideline-directed medical therapy in multimorbid patients with HFpEF
引领照护——在多重共病 HFpEF 患者中实施最优指南指导药物治疗
Leading care – implementing optimal guideline-directed medical therapy in multimorbid patients with HFpEF
Novo Nordisk
GLP-1 受体激动剂用于肥胖驱动型 HFpEF：从指南到实践
Clinical translation of GLP-1RAs for adiposity-driven HFpEF: from guidelines to practice
开场与欢迎
Opening and welcome
HFpEF 中的肥胖：疾病病理生理的关键驱动因素
Adiposity in HFpEF: a key driver of disease pathophysiology
肥胖相关 HFpEF 中的肠促胰素疗法：从证据到指南
Incretin therapies in adiposity-related HFpEF: from evidence to guidelines
探索下一代肠促胰素疗法：洞见与机遇
Exploring next-generation incretin therapy: insights and opportunities
GLP-1 受体激动剂用于肥胖驱动 HFpEF 的临床转化：从指南到实践——问答
Clinical translation of GLP-1RAs for adiposity-driven HFpEF: from guidelines to practice - questions and answers
心肾交互2 个系列
AstraZeneca
为何心衰患者仍未见好转：残余风险与心肾缺口
Why your heart failure patient still isn’t improving: residual risk and the cardiorenal gap
欢迎与课前评估
Welcome and pre-assessment
为什么合并肾功能损害的衰竭患者在现代诊疗下结局仍不佳
Why heart failure patients with kidney impairment still do poorly despite modern care
为什么我们在高危心力衰竭患者中仍未能优化治疗？
Why are we still failing to optimise therapy in high-risk heart failure patients?
超越今日之诊疗：降低残余风险需要什么？
Beyond today’s care: what will it take to reduce residual risk?
专家讨论与问答：实践中我们应做出哪些改变？
Expert discussion and Q&A: what should we do differently in practice?
为什么你的心力衰竭患者仍未改善：残余风险与心肾差距——闭幕致辞
Why your heart failure patient still isn’t improving: residual risk and the cardiorenal gap - Closing remarks
AstraZeneca
优化心肾照护：改善患者结局
Optimising cardiorenal care: enabling better patient outcomes
优化心肾照护：促成更好的患者结局
Optimising cardiorenal care: enabling better patient outcomes
心衰远程管理与药物滴定2 个系列
Servier
从指南到临床获益：指南指导治疗落地还缺什么
From guidelines to clinical impact: what are the missing pieces to successful guideline-directed medical therapy implementation?
引言
Introduction
有效治疗、影响落空：心力衰竭的悖论
Effective treatments, missed impact: the heart failure paradox
心衰指南：依从性与指南指导药物治疗实施的地位
Heart failure guidelines: the place of adherence and guideline-directed medical therapy implementation
应对紧迫需求的务实方案：如何在真实世界环境中实现临床试验结果
Pragmatic solutions for pressing needs: how to achieve clinical trial results in the real-world setting
从指南到临床影响：成功的指南指导药物治疗实施还缺什么？——讨论与问答
From guidelines to clinical impact: what are the missing pieces to successful guideline-directed medical therapy implementation? - Discussion and Q&A
从指南到临床影响：成功的指南指导药物治疗实施还缺什么？——总结
From guidelines to clinical impact: what are the missing pieces to successful guideline-directed medical therapy implementation? - Conclusion
AstraZeneca
高钾血症管理入门：助力 RAAS 抑制剂优化使用
Hyperkalaemia management 101: supporting renin-angiotensin-aldosterone system inhibitors optimisation
高钾血症管理入门：支持肾素-血管紧张素-醛固酮系统抑制剂优化
Hyperkalaemia management 101: supporting renin-angiotensin-aldosterone system inhibitors optimisation
综合与其他7 个系列
Carmat
超越移植等待：晚期心衰的生理性心脏替代治疗兴起
Beyond transplantation waiting: the rise of physiologic heart replacement therapy in advanced heart failure
谁需要全人工心脏？2026 年重新定义候选患者
Who needs a total artificial heart? Redefining the candidate in 2026
植入全人工心脏：欧洲经验告诉我们什么
Implanting a total artificial heart: what the European experience tells us
与全人工心脏共存：功能恢复、生活质量与移植之路
Life with a total artificial heart: functional recovery, quality of life and the road to transplantation
超越移植等待：晚期心衰生理性心脏替代治疗的兴起——问答
Beyond transplantation waiting: the rise of physiologic heart replacement therapy in advanced heart failure - Q&A
Siemens Healthineers
肝病患者的心脏超声评估与随访（系列共 2 场）
Cardiac evaluation and follow-up with echo, in liver disease
肝病患者的超声心动图心脏评估与随访
Cardiac evaluation and follow-up with echo, in liver disease
Boehringer Ingelheim
心脏科交流中心：真实世界心衰管理实践（系列共 10 场）
Cardiology exchange hub: navigating real-world heart failure management
心脏病学交流站：真实世界心衰管理导航
Cardiology exchange hub: navigating real-world heart failure management
Boehringer Ingelheim
SGLT2 抑制剂与醛固酮合酶抑制剂是心血管治疗的下一前沿吗
Is SGLT2i/ASi the next frontier in advancing cardiovascular care?
欢迎与介绍
Welcome and introduction
当前基础治疗：基于病例的介绍
Current foundational therapy: a case-based introduction
靶向 RAAS 过度激活：SGLT2 抑制剂/醛固酮合酶抑制剂的依据
Targeting RAAS overactivation: the rationale for SGLT2i/ASi
通过广泛的大规模试验项目研究 SGLT2 抑制剂/醛固酮合酶抑制剂
Investigating SGLT2i/ASi through broad, large-scale trial programs
回顾我们的患者病例：不断演进的心肾治疗
Revisiting our patient case: evolving cardiorenal care
专家讨论与问答
Panel discussion and Q&A
… 另 1 项讲题
Abbott
质疑晚期心衰的金标准：延长生命年数（系列共 2 场）
Questioning the gold standard for advanced heart failure patients - Adding years to life
质疑晚期心力衰竭患者的金标准——延长生命年
Questioning the gold standard for advanced heart failure patients - Adding years to life
Bayer AG
为何可溶性鸟苷酸环化酶激动剂应纳入 HFrEF 治疗药物库
Why should soluble guanylate cyclase stimulation be part of your medication toolkit for heart failure with reduced ejection fraction?
为什么可溶性鸟苷酸环化酶刺激应成为你 HFrEF 药物治疗工具箱的一部分？
Why should soluble guanylate cyclase stimulation be part of your medication toolkit for heart failure with reduced ejection fraction?
Bayer AG
一个都不落下：优化新诊断心衰患者的治疗（系列共 2 场）
No one left behind – Optimising therapies in newly diagnosed patients with heart failure
不让任何人掉队——优化新诊断心衰患者的治疗
No one left behind – Optimising therapies in newly diagnosed patients with heart failure
企业卫星会内容由赞助方支持，此处仅作学术日程信息陈列，不代表编辑立场。